CombiGene AB (SE:LARK)

:LARK

LARK

CombiGene AB

RESEARCH TOOLSreports

Want to see SE:LARK full AI Analyst Report?

CombiGene AB (LARK) Price & Analysis

0 Followers

LARK Stock Chart & Stats

kr2.35

Market closed

kr2.35

Day’s Range― - ―

52-Week Rangekr1.75 - kr2.87

Previous CloseN/A

VolumeN/A

Average Volume (3M)41.41K

Market Cap

kr46.14M

Enterprise Value-kr14.34M

Total Cash (Recent Filing)kr60.28M

Total Debt (Recent Filing)kr0.00

Price to Earnings (P/E)―

Beta0.08

Next Earnings

Aug 21, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield8.47%

Share Statistics

EPS (TTM)-1.78

Shares Outstanding19,801,197

10 Day Avg. Volume70,026

30 Day Avg. Volume41,406

Financial Highlights & Ratios

PEG Ratio-0.04

Price to Book (P/B)0.66

Price to Sales (P/S)144.56

P/FCF Ratio-1.57

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Debt-Free Balance SheetA debt-free balance sheet reduces financial risk and refinancing pressure, providing flexibility for future strategic investments.

Gene-Therapy FocusThe focus on gene-therapy for neurological diseases positions the company in a high-potential market with growing demand for innovative treatments.

Cash Flow TrackingClose tracking of cash flow to net income indicates efficient cash management, which is crucial for sustaining operations during loss-making periods.

Bears Say

Revenue DeclineA sharp decline in revenue indicates challenges in maintaining sales momentum, which could hinder long-term growth and market competitiveness.

Sustained Cash BurnSustained cash burn reflects ongoing financial strain, potentially limiting the company's ability to invest in R&D and future growth initiatives.

Equity DeclineA decline in equity suggests value erosion, which could impact investor confidence and the company's ability to raise capital in the future.

LARK FAQ

What was CombiGene AB’s price range in the past 12 months?

CombiGene AB lowest stock price was kr1.75 and its highest was kr2.87 in the past 12 months.

What is CombiGene AB’s market cap?

CombiGene AB’s market cap is kr46.14M.

When is CombiGene AB’s upcoming earnings report date?

CombiGene AB’s upcoming earnings report date is Aug 21, 2026 which is in 62 days.

How were CombiGene AB’s earnings last quarter?

CombiGene AB released its earnings results on Feb 13, 2026. The company reported kr0.01 earnings per share for the quarter, beating the consensus estimate of N/A by kr0.01.

Is CombiGene AB overvalued?

According to Wall Street analysts CombiGene AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does CombiGene AB pay dividends?

CombiGene AB pays a Notavailable dividend of kr2 which represents an annual dividend yield of 8.47%. See more information on CombiGene AB dividends here

What is CombiGene AB’s EPS estimate?

CombiGene AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does CombiGene AB have?

CombiGene AB has 19,801,197 shares outstanding.

What happened to CombiGene AB’s price movement after its last earnings report?

CombiGene AB reported an EPS of kr0.01 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -3.83%.

Which hedge fund is a major shareholder of CombiGene AB?

Currently, no hedge funds are holding shares in SE:LARK

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

CombiGene AB

Lärkberget AB (publ) functions as an investment firm, engaging in a variety of financial endeavors. Its operations encompass direct capital deployment into low-risk instruments, broader financial investments, acquiring stakes in privately held yet profitable companies, and serving as a vehicle for reverse acquisitions. Established in 1990 and based in Östermalm, Sweden, the company transitioned to its current name, Lärkberget AB (publ), in June 2025, having formerly operated as CombiGene AB (publ).